Oral PCSK9 pills cut LDL cholesterol by up to 61.8 points in trials

PCSK9 inhibitors are among the most powerful cholesterol-lowering drugs available, but the existing versions are injections, and they remain under-used because of cost, the subcutaneous route, cold-chain storage and patient preference. A pill that did the same job could reach far more people with stubbornly high LDL cholesterol. Three oral PCSK9 inhibitors, two peptide-based agents and one small molecule, have recently completed phase 3 testing. This analysis pooled the trial evidence to ask how much these pills lower LDL, whether higher doses do more, and whether any agent or dose stands out from the pack.

The researchers searched four databases up to 1 May 2026 for randomised trials comparing oral PCSK9 inhibitors with placebo. They then ran a network meta-analysis that treated every drug and dose combination as its own entry, which allows indirect comparisons between pills that were never tested against each other directly. The primary outcome was the mean percentage change in LDL cholesterol from baseline, and the certainty of the evidence was formally rated. Five trials covering 4,227 participants and twelve drug-dose combinations were included.

All twelve drug-dose combinations lowered LDL cholesterol compared with placebo. The largest reductions came from NNC0385-0434 at 100 mg, 61.8 percentage points below placebo, with MK-0616 close behind at 60.9 points for the 30 mg dose and 58.5 points for 20 mg. Higher doses reliably did more for all three agents. Crucially, none of the comparisons among the four highest-ranked doses reached significance and their rankings overlapped, so no winner emerged. Other lipid measures also improved, far more participants reached cholesterol goals, no short-term safety signal appeared, and the disagreement between studies traced to the timepoint compared, disappearing at week 24.

This is a pooled picture of the oral PCSK9 inhibitor class after phase 3, and it shows the pills deliver large placebo-adjusted reductions, though the analysis made no direct comparison with the injectable versions. The authors rate the certainty of the evidence as low, largely because almost all comparisons between agents were indirect rather than head to head. Open questions remain about long-term safety and about outcomes that matter most, since this analysis covered cholesterol changes and short-term safety rather than heart attacks or strokes.

For anyone whose LDL cholesterol stays high and who finds injections or their storage demands a barrier, this is a signal that a pill route through the same drug target has now cleared late-stage trials. The reductions versus placebo were large and grew with dose, which is encouraging, but nobody can yet say which pill or dose is best, and safety has only been tracked over the short term. These are prescription medicines under evaluation, so this is information about where cholesterol treatment is heading rather than anything to act on now.